Processa Pharmaceuticals, Inc. Total Long-Term Debt
Processa Pharmaceuticals, Inc. (PCSA) had Total Long-Term Debt of $27.51 thousand as of 2015-09-30, per its 10-Q filed 2015-12-01.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2015-12-01
- 2015-09-30: Long-term Debt $27.51K.
| Period end | Long-term Debt |
|---|---|
| 2015-09-30 | $27.51K 10-Q · filed 2015-12-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |